

Haematologica
HAEMATOL/2018/205096
Version 3

Mogamulizumab versus investigator choice of chemotherapy regimen
in relapsed/refractory adult T-cell leukemia/lymphoma

Adrienne A. Phillips, Paul A. Fields, Olivier Hermine, Juan C. Ramos,
Brady E. Beltran, Juliana Pereira, Farooq Wandroo, Tatyana Feldman,
Graham P. Taylor, Ahmed Sawas, Jeffrey Humphrey, Michael Kurman,
Junji Moriya, Karen Dwyer, Mollie Leoni, Kevin Conlon, Lucy Cook,
Jason Gonsky, and Steven M. Horwitz

Disclosures: J.H., M.K., J.M., K.D., and M.L. are or have been employees of Kyowa Kirin; A.A.P. has received research funding from Kyowa Kirin, and financial compensation for providing advisory/consulting roles to Kyowa Kirin, Celgene, and Genentech; S.M.H. has received research funding from Kyowa Kirin, Celgene, Millenium/Takeda, Seattle Genetics, Forty-Seven, BMS, Infinity/Verastem, ADCT Therapeutics and Aileron Therapeutics, financial compensation as honoraria or for providing advisory/consulting roles to Kyowa Kirin, Celgene, Millenium/Takeda, Seattle Genetics, Forty-Seven, BMS, and Mundipharma, and reimbursement of travel/accommodation/expenses from Kyowa Kirin; L.C. has received financial compensation for providing advisory/consulting roles to Kyowa Kirin and Innate Pharma, honoraria from Roche, and speakers bureau fees from Gilead; T.F. has received financial compensation for travel/accommodation/expenses from Kyowa Kirin, and honoraria for consultancy/speakers bureau from Seattle Genetics, Takeda, BMS, Pharmacyclics/Janssen, AbbVie, Celgene, and Kite Pharma; F.W. has received financial compensation as an educational grant from Gilead, financial compensation for providing an advisory/consulting role to Pfizer, speakers bureau fees from BMS, Roche, and Boehringer, and reimbursement of travel/accommodation/expenses from Celgene and Gilead; G.P.T. has received research funding from Kyowa Kirin; J.P. has received speakers bureau fees from Roche and Genentech, and has received financial compensation for providing an advisory/consulting role to Libbs; J.C.R. has received honoraria from Cardinal Health, financial compensation for providing advisory/consulting role to Cardinal Health, and reimbursement travel/accommodation/expenses from Cardinal Health and miRagen Therapeutics; AS has received financial compensation for providing advisory/consulting roles to Kyowa Kirin; the remaining author (K.C.) declares no competing financial interests.

Contributions: S.M.H., A.A.P., J.G., P.A.F., O.H., G.P.T., K.C., J.C.R., J.H., K.D., and M.K. conceived and designed the study; A.A.P., J.C.R., G.P.T., P.A.F., L.C., F.W., O.H., T.F., B.E.B., J.P., S.M.H., AS and K.C. provided study materials or patients; A.A.P., J.C.R., G.P.T., P.A.F., L.C., F.W., O.H., T.F., B.E.B., J.P., S.M.H., AS and K.C. acquired data; S.M.H., A.A.P., J.G., M.L., M.K., J.M. and K.D. analyzed and interpreted the data; and all authors were involved in writing the manuscript and gave final approval.